Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 1, 1996

View Archived Issues

Dong-A's analgesic drug candidate in clinical trials

New method of total synthesis of epibatidine reported

Lanepitant in clinical trials for pain

Spotlight on NK1 antagonists

Hybridon researches VEGF/VPF antisense compounds for skin disorders

Roche describes retinoid compounds for acne, cancer

Advanced Polymer Systems and Medicis sign agreement for dermatology products

Cefzil approved for new indication in U.S.

New antibiotic from Sankyo

Sankyo prepares pseudomonic acid derivatives

Potent antifungal agent described by Morishita Roussel

Mentax approved for marketing

Another approval for Abelcet and further patent coverage

Anti-HIV agents from Sankyo

HIV protease inhibitors reported by Searle

Agouron to file NDA for Viracept

GEM-91 clinical trials update

Japanese researchers report natural DHFR inhibitors

Antiarthritic agents reported by Kaken

ADIR investigates COX-2 inhibitors

Collagenase inhibitor from Roche for arthritic conditions

PDL signs agreement with Roche for humanized antibody

Prolonged treatment with Salagen Tablets not associated with tachyphylaxis

Zenapax enters clinical trials for uveitis

Takeda discloses vaccine candidates

Three-dimensional structure of the T-cell receptor determined

Novel DNA vaccine induces immune response to HSV-2

StressGen's core technology receives patent protection

Polyamine antimetabolites claimed by Ciba-Geigy

Taxotere now approved in 35 countries

HHS claims MAb for therapeutic, diagnostic and immunologic applications

Antitumor antibody for medulloblastoma Rx claimed by Chugai

First gene gun clinical trial announced by Auragen

PDL signs humanized antibody agreement with Japanese company

Peregrine seeks partners for development of vascular targeting agents

Cell adhesion inhibitors reported by Sumitomo

Antitumor organotin compounds claimed by Dutch company

Low-toxicity antitumor agents described by Ajinomoto

New synthetic process for swainsonine should facilitate clinical testing

Hybridon questions role of CAPL in cancer metastasis

Hybridon's 1729 for multi-drug-resistant cancers

Hybridon's VEGF-targeting antisense drugs for retinal neovascularization

Lilly continues to investigate new agents for women's health

Canadian researchers claim hPTH analogues for osteoporosis

Mitsubishi to copromote OrthoLogic 1000 in Japan

FCP-3P1 in Canadian clinical trials

CRADA opportunity for the treatment of atherosclerosis and LCAT deficiency

Antiobesity proteins described by Lilly

Lilly and Neurocrine collaborate in the areas of obesity and Alzheimer's disease

Oncogene awarded drug discovery grant

Sheffield Medical Technologies and Alpha Therapeutic enter into option agreement

MRI contrast agents from Nycomed Salutar

Schering AG describes radiographic contrast agent

Third-generation ultrasound contrast agent from Sonus

Diatide's P483H Techtide receives patent protection in U.S.

Eiken contrast agents in development

InSite Vision strengthens position on genetic research into glaucoma

Melatonergic agents reported by BMS

Anxiolytic activity of phytomedicine established in patients

Pfizer 5-HT reuptake inhibitor approved in U.S. for new indication

Xenova, Warner-Lambert sign drug discovery collaborative agreement

3-Dimensional Pharmaceutical's DirectedDiversity technology for drug discovery

Varian, Stanford University and SRI collaborative agreement aimed at new cancer cures

Andrx drug delivery technology receives patent coverage

Strategy and outlook for HemaSure's blood pathogen inactivation system

Lynx signs two agreements with BASF

CellPro to begin clinical trial of T-cell depletion system

BMS establishes Hungarian R&D office

AccuMed to obtain interest in Oncometrics

Name change for Ciba Corning Diagnostics

Definitive Gelman Sciences merger agreement

N-type calcium channel blockers from Sankyo

Merck NK1 antagonist shows antiemetic activity in ferrets

Meiji Seika discloses compounds that enhance axonal regeneration

Eisai files for approval of Aricept

Alzheimer's disease linked to immunoinflammatory response

Japanese researchers disclose glutamate antagonists

Pfizer describes a new series of CRF antagonists

NPS Pharm. selects NMDA antagonist for further testing

Dual H1/NK1 antagonists as potential antiallergics

New antiallergic agents from Takeda

NK1/NK2 antagonist research at Hoechst Marion Roussel

Nonpeptide NK1/NK2 antagonist identified by Merck & Co.

R-Albuterol for pediatric asthma

UCSF scientists discover new gene therapy approach to CF

Favorable results reported for Targeted Genetics' CF gene therapy

Ono discloses cGMP-PDE/TxA2 synthase inhibitors

New dual ACE/NEP inhibitors claimed by Bristol-Myers Squibb

VasoCare therapy for hypertension

Tyrosine kinase inhibitor for restenosis

Na+ channel inhibitor as cardioprotectant

CPC-111 clinical results presented at congress

Atlantic's CT-1 and CT-2 prevent restenosis

Hoechst claims new antiarrhythmic agents

Safer antiarrhythmic agent reported by Canadian researchers

Antiarrhythmic 1,4-benzodiazepine from Merck

cGMP-PDE inhibitors described by Sanofi Winthrop

Berlex discloses factor Xa inhibitors

Factor Xa/thrombin inhibitors from Roche

Potential use of phytopharmaceutical compounds for BPH

Terumo discloses agents with activity against H. pylori

Merck & Co. describes CCK/gastrin antagonists

Novel antiulcer agents reported by Arax

Boehringer Ingelheim claims 5-HT4 antagonists for various indications

Vertex solves HCV protease structure

Hypoglycemic agents disclosed by Yamanouchi

Lilly reports long-acting, soluble insulin analogues

Pulmonary-delivered insulin advances through clinical trials

Growth hormone secretion stimulants claimed by Merck & Co.

FDA begins review of Oxandrin

New, more convenient testosterone transdermal patch submitted for approval

TheraTech's testosterone patch now being tested in women with sexual dysfunction

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 12, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...